Clinical Research Directory

Inclusion Criteria: * Patients aged 18-55 years, inclusive * Diagnosis of RRMS (McDonald Criteria 2017 and Lublin phenotype classification 2014) * Expanded disability status scale (EDSS) score less than or equal to 5.5 * Patients receiving a first line treatment with teriflunomide or dimethyl fumarate at a stable dose, for at least 24 weeks, or patients who are not receiving treatment because they do not want to receive a DMT after the investigator has informed them of their possible respective benefits and possible adverse events * At enrollment, the patient is not expected to require a change in DMT * Patients showing a maximum of two new lesions on MRI prior to inclusion * Females of childbearing potential must have a negative urine pregnancy test result prior to initiation of study product * For females of childbearing potential: agreement to use adequate contraceptive methods during the treatment period * Ability to comply with the study protocol * Patients must sign and date a written informed consent prior to entering the study Exclusion Criteria: * Relapse the month before enrollment * Presence of a new lesion, indicative of radiological activity, on the MRI performed before starting the study * Use of corticosteroids the month before enrollment * Use of antibiotics three months before enrollment * Taking other forms of symbiotic, probiotic, prebiotic and postbiotic supplements three months before enrollment * Patients suffering from any type of bowel disease * Pregnant or breastfeeding or intending to become pregnant during the study. * Be menopausal * Be a smoker